Tolerability and adherence issues in antidepressant therapy.
about
Creatine metabolism and psychiatric disorders: Does creatine supplementation have therapeutic value?Citalopram plus low-dose pipamperone versus citalopram plus placebo in patients with major depressive disorder: an 8-week, double-blind, randomized study on magnitude and timing of clinical responseChanges in body weight and psychotropic drugs: a systematic synthesis of the literature"A feeling of connectedness": perspectives on a gentle yoga intervention for women with major depression.The impact of medication regimen factors on adherence to chronic treatment: a review of literature.Cost-efficient treatment for uninsured or underinsured patients with hypertension, depression, diabetes mellitus, insomnia, and gastroesophageal reflux.Coverage of atypical antipsychotics among medicare drug plans in the state of washington: changes between 2007 and 2008.Early prediction of acute antidepressant treatment response and remission in pediatric major depressive disorder.Exercise improves sexual function in women taking antidepressants: results from a randomized crossover trialQuality of care associated with common chronic diseases in a 9-state Medicaid population utilizing claims data: an evaluation of medication and health care use and costs.Treatment patterns, healthcare resource utilization, and costs following first-line antidepressant treatment in major depressive disorder: a retrospective US claims database analysis.Adverse effects from antidepressant treatment: randomised controlled trial of 601 depressed individualsExpenditures associated with dose titration at initiation of therapy in patients with major depressive disorder: a retrospective analysis of a large managed care claims database.Pharmacogenetics of antidepressant response.Major Depressive Disorder and Kappa Opioid Receptor Antagonists.Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder.A Depression Recognition and Treatment package for families living with Stroke (DepReT-Stroke): study protocol for a randomised controlled trial.Early adverse events and attrition in selective serotonin reuptake inhibitor treatment: a suicide assessment methodology study report.Exploring the role of drug-metabolising enzymes in antidepressant side effects.Understanding Statin Non-Adherence: Knowing Which Perceptions and Experiences Matter to Different Patients.Antidepressant adherence: are patients taking their medications?Treating major depression with yoga: A prospective, randomized, controlled pilot trialTreatment discontinuation and tolerability as a function of dose and titration of duloxetine in the treatment of major depressive disorderPost-traumatic stress disorder: an evaluation of existing pharmacotherapies and new strategies.Should treatment for depression be based more on patient preference?A Randomized, Double-blind Study of the Efficacy and Tolerability of Extended Release Quetiapine Fumarate (Quetiapine XR) Monotherapy in Patients with Major Depressive Disorder.Depression and stroke: a common but often unrecognized combination.Improving adherence in mood disorders: the struggle against relapse, recurrence and suicide risk.A randomized, double-blind study of the efficacy and tolerability of extended-release quetiapine fumarate (quetiapine XR) monotherapy in patients with major depressive disorder.Antidepressants in primary care: patients' experiences, perceptions, self-efficacy beliefs, and nonadherence.Desvenlafaxine for major depressive disorder: incremental clinical benefits from a second-generation serotonin-norepinephrine reuptake inhibitor.Treatment duration with selective serotonin reuptake inhibitors among children and adolescents in Finland: a nationwide register study.Effects of depressive and other psychiatric disorders on anticoagulation control in a pharmacist-managed anticoagulation clinic.Vortioxetine versus Duloxetine in the Treatment of Patients with Major Depressive Disorder: A Meta-Analysis of Randomized Controlled Trials.Evaluation of the potential antidepressant effects of soybean isoflavones.Primary-care patients' trade-off preferences with regard to antidepressants.Prevalence of non-adherence among psychiatric patients in Jordan, a cross sectional study.Antidepressant therapy in cancer patients: initiation and factors associated with treatment.Safety Assessment of Liver Injury with Quetiapine Fumarate XR Management in Very Heavy Drinking Alcohol-Dependent Patients.Discontinuing treatment for psychiatric disorders.
P2860
Q24631151-EAAE9EF4-8F32-4342-8F60-AC82C985D4DAQ28306033-A530FD2A-2FB1-4E0F-81BE-3E3D2353FD6AQ28728401-15FD0C43-517A-45B8-A02C-9B0A28C7BF26Q30412795-B412CE55-96B4-44AD-B63D-8B76BD31E676Q30436145-3E667CF7-8482-4985-95CE-3295FFECF4D4Q33323489-24AABE79-2D32-4ED1-85B8-2055C56D4E74Q33587010-B455216F-31A3-4B0E-BB90-2356C522620EQ33655082-13680F4C-9861-4D49-B1C3-F06E635256ECQ33690148-E7CAA8C0-54B0-49AE-8ED3-EDD64239DE62Q33766337-7885B647-61EB-4D95-89AB-9214CD5C39D7Q33814867-8308A956-389A-44F9-9BDA-07C91B289620Q33906501-4D0F050A-5871-4EEE-BE4F-E1CF3B14F98CQ34111309-CC14E113-561A-4C4D-898F-2B4B92EA4DA5Q34155796-C9D7B6FD-BF01-4080-A6F1-9839F3358913Q34527874-E965C227-7D5E-4733-A081-082E5435E110Q34871885-FCF2F962-B4BC-4E25-99F2-AEFC3751C6F5Q34988864-4D11133E-8E5B-4393-85D6-07E08771BE7EQ35058467-A73798E0-9F4C-48A3-9116-73FBCFA01ED6Q35780023-8DFF5F50-C575-4E56-9AF9-19D677AA5791Q35903382-128E4E2D-3FAD-4D1E-B8EC-BF7E1AB263F3Q36100180-85FF4651-ADA0-4583-BF0E-93F8B1A05E99Q36310727-747F6DB0-06A3-4AC9-944F-D9B3A8B6F0A9Q36467627-A66F0DEB-3F7A-4374-932F-DF63D2E7BA7BQ36909270-10E54C30-2728-4E63-A8BF-1DB5896E1D9CQ37232239-50F905C0-475E-44D8-BA65-879BA60E3317Q37299884-79B152D8-AD4A-4E2A-8498-DB6359ECFE72Q37426249-0FED1E5A-26D8-46A1-8485-C8BD826C7D4EQ37546078-8569EB75-6763-4D7B-90B7-95F688D32D6DQ37562207-C863A78B-9403-43E9-801B-8A3E963E84B1Q37588434-7B9D0F1D-995C-4D61-A1F8-7942CB4155F8Q37808483-7D5C5C77-BEA1-4B9F-8F2F-0D830A566C3AQ37983502-492A37BB-7797-4B2F-9DDA-3978A0FB30D4Q38164681-2B421292-2FF7-45F6-9599-D5FA1CF53877Q38805096-9F94629E-97D6-4DE5-A849-6C084FE727CEQ38828677-1C3A7BD1-04C1-4260-B1F2-45EA586D6555Q39214070-BAC1C0B4-B9E4-4E76-8419-7CB346BA3AC8Q40063216-DA7FFD10-647B-4794-97B8-CFAAD2BB7A23Q41096140-3DB7AB9F-FC27-4A6D-AA61-F2169D2F0224Q42733571-B859F03B-FF77-43A0-9D2C-840853E0BF57Q43151986-4D418063-E881-4E76-A6C5-61CF36C5EB7B
P2860
Tolerability and adherence issues in antidepressant therapy.
description
2003 nî lūn-bûn
@nan
2003 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Tolerability and adherence issues in antidepressant therapy.
@ast
Tolerability and adherence issues in antidepressant therapy.
@en
type
label
Tolerability and adherence issues in antidepressant therapy.
@ast
Tolerability and adherence issues in antidepressant therapy.
@en
prefLabel
Tolerability and adherence issues in antidepressant therapy.
@ast
Tolerability and adherence issues in antidepressant therapy.
@en
P1476
Tolerability and adherence issues in antidepressant therapy.
@en
P2093
Prakash S Masand
P304
P356
10.1016/S0149-2918(03)80220-5
P577
2003-08-01T00:00:00Z